U.S. License Holder:
Date of License:
NYVEPRIA (pegfilgrastim-apgf) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Nyvepria® (Pfizer) (November-2020)
Inter Partes Review ProceedingsPTAB Portal
IPR Case No(s):
U.S. Patent No.
8,273,707 (Process for Purifying Proteins)
Hospira, Inc.; Pfizer Inc.
§ 102 Challenge
Claim Types Challenged Under § 102
§ 102 Challenge Instituted
§ 103 challenge
Claim Types Challenged Under § 103
§ 103 Challenge Instituted
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)
Terminated After Institution Due to Settlement